The Capital Partnership
The Capital Partnership is an independent asset manager established in 1998, based in London, with additional offices in Dubai. It provides a diverse range of asset management and wealth preservation services to institutional and private investors, including families and large institutions in the EMEA region. Initially created to serve the sophisticated investment needs of the founding partners' families, the firm has successfully expanded its offerings to address the asset management requirements of various clients. The Capital Partnership employs a multi-strategy approach, investing in both public and private markets. The group's ultimate holding company is incorporated in the Dubai International Financial Centre, while its UK operating subsidiary is authorized and regulated by the Financial Conduct Authority. Through its expertise, The Capital Partnership assists clients in navigating the complexities of asset growth and preservation.
28 past transactions
Supira Medical
Series E in 2025
Supira Medical, Inc. is a medical technology company based in Campbell, California, focused on developing a percutaneous ventricular assist device (pVAD) designed for high-risk patients undergoing interventional procedures. This innovative device offers high-flow mechanical support during critical situations such as high-risk percutaneous coronary interventions (PCI) and cardiogenic shock. By assisting the heart's native pumping action, Supira Medical's solution enables patients with severe coronary artery disease or related comorbidities to safely undergo necessary interventions, thereby facilitating quicker recovery from heart-related issues. Founded in 2012 and originally known as Lumenblation Medical, Inc., the company rebranded in March 2016 to reflect its commitment to advancing cardiac care.
Laza Medical
Series A in 2023
Laza Medical is a privately held startup dedicated to the development of advanced medical imaging solutions specifically for cardiovascular treatments. The company focuses on creating an AI-powered robotic imaging system designed to enhance the quality and efficiency of cardiac interventions. By leveraging artificial intelligence and robotics, Laza Medical aims to optimize procedural workflows and elevate imaging standards in the healthcare sector. Their innovative technology seeks to provide high-quality imaging and improved navigation during procedures, making it accessible to a wide range of clinicians through an intuitive user interface.
Supira Medical
Series D in 2023
Supira Medical, Inc. is a medical technology company based in Campbell, California, focused on developing a percutaneous ventricular assist device (pVAD) designed for high-risk patients undergoing interventional procedures. This innovative device offers high-flow mechanical support during critical situations such as high-risk percutaneous coronary interventions (PCI) and cardiogenic shock. By assisting the heart's native pumping action, Supira Medical's solution enables patients with severe coronary artery disease or related comorbidities to safely undergo necessary interventions, thereby facilitating quicker recovery from heart-related issues. Founded in 2012 and originally known as Lumenblation Medical, Inc., the company rebranded in March 2016 to reflect its commitment to advancing cardiac care.
Akura Medical
Series B in 2023
Akura Medical is focused on advancing medical technology through the development of innovative thrombectomy devices. The company aims to simplify the clot removal process with a next-generation device designed for an easy-to-use, single-pass procedure that effectively extracts blood clots. In addition to its thrombectomy offerings, Akura Medical provides a range of surgical, medical, dental, and veterinary apparatus and instruments. This diverse product portfolio enables healthcare professionals to address critical medical needs and enhances the treatment of venous thromboembolism across various applications.
Myra Vision
Series B in 2023
Myra Vision is a medical technology company focused on developing innovative treatments for patients with moderate to severe glaucoma. The company aims to enhance intraocular pressure (IOP) reduction through its advanced surgical techniques, which also minimize the risk of hypotony. By addressing the existing gaps in glaucoma therapies, Myra Vision seeks to provide effective solutions that improve patient outcomes and support physicians in managing this challenging condition. Through its novel technology, the company is committed to advancing glaucoma care and improving the quality of life for affected individuals.
Tioga Cardiovascular
Series C in 2023
Tioga Cardiovascular is a privately held company that specializes in developing valve replacement solutions for mitral and tricuspid applications. The company focuses on creating medical equipment technology that employs a transcatheter approach, which is both procedurally simpler and less invasive than traditional methods. By prioritizing innovation in valve replacement devices, Tioga Cardiovascular aims to enhance the effectiveness and success of heart surgeries, thereby improving patient outcomes and providing elegant solutions for healthcare professionals.
Atia Vision
Series E in 2022
Atia Vision, Inc. is a medical device company based in Campbell, California, specializing in the development of innovative ophthalmic solutions. Founded in 2012, the company focuses on creating modular presbyopia-correcting intraocular lenses, which address the needs of the intraocular lens replacement market. Atia Vision's technology features an accommodating base that responds to the ciliary muscles of the eye, simulating natural accommodation and allowing for subsequent refractive corrections. This approach restores the full range of functional vision for cataract patients, effectively improving patient outcomes by eliminating the need for glasses. The company's commitment to advancing eye care is reflected in its goal to enhance the quality of life for individuals through innovative medical devices that expedite market entry while minimizing risk.
Adona Medical
Series B in 2022
Adona Medical is a privately held company focused on innovating interventional approaches for heart failure management, a condition affecting approximately 6.5 million patients in the United States and around 26 million globally. The company develops a heart failure management system that enhances the standard of cardiac care through advanced sensor and shunt technologies. This system allows healthcare providers to personalize and tailor treatments for heart failure patients, addressing individual needs more effectively. Adona Medical's interatrial shunt technology provides valuable insights into a patient's hemodynamic status, ultimately aiming to improve care and outcomes for those suffering from this complex and progressive condition.
Supira Medical
Series C in 2022
Supira Medical, Inc. is a medical technology company based in Campbell, California, focused on developing a percutaneous ventricular assist device (pVAD) designed for high-risk patients undergoing interventional procedures. This innovative device offers high-flow mechanical support during critical situations such as high-risk percutaneous coronary interventions (PCI) and cardiogenic shock. By assisting the heart's native pumping action, Supira Medical's solution enables patients with severe coronary artery disease or related comorbidities to safely undergo necessary interventions, thereby facilitating quicker recovery from heart-related issues. Founded in 2012 and originally known as Lumenblation Medical, Inc., the company rebranded in March 2016 to reflect its commitment to advancing cardiac care.
Mindstep
Seed Round in 2022
Mindstep is a developer of cognitive and mental health digital therapeutics, with a mission to improve brain health and reduce the risk of dementia for one million individuals. Founded by medical professionals, the company prioritizes accessibility, empathy, and scientific rigor, reflecting core values typical of the NHS. Mindstep utilizes a platform that merges machine learning with clinical research, creating digital solutions that provide users with a personalized healthcare experience. By enabling users to screen themselves for dementia and access quality care, Mindstep aims to overcome traditional healthcare capacity limitations, effectively placing a digital clinic in every patient's pocket.
Akura Medical
Series A in 2022
Akura Medical is focused on advancing medical technology through the development of innovative thrombectomy devices. The company aims to simplify the clot removal process with a next-generation device designed for an easy-to-use, single-pass procedure that effectively extracts blood clots. In addition to its thrombectomy offerings, Akura Medical provides a range of surgical, medical, dental, and veterinary apparatus and instruments. This diverse product portfolio enables healthcare professionals to address critical medical needs and enhances the treatment of venous thromboembolism across various applications.
Elemy
Series B in 2021
Elemy is a nationwide provider of childhood behavioral and mental healthcare, specializing in autism care since its launch in April 2020. The company has expanded its services to address a range of developmental and mental health issues, including ADHD, OCD, depression, and social anxiety. Elemy employs a technology-driven care model that modernizes traditional systems by offering in-home and online Applied Behavior Analysis (ABA) services. This approach enhances accessibility and clinical outcomes while reducing costs. The platform features free autism assessments and matches children with therapists to create individualized treatment plans tailored to their specific needs. Elemy's multidisciplinary clinical team oversees an integrated care model, demonstrating significant improvements in behavior for many children.
Tioga Cardiovascular
Series B in 2021
Tioga Cardiovascular is a privately held company that specializes in developing valve replacement solutions for mitral and tricuspid applications. The company focuses on creating medical equipment technology that employs a transcatheter approach, which is both procedurally simpler and less invasive than traditional methods. By prioritizing innovation in valve replacement devices, Tioga Cardiovascular aims to enhance the effectiveness and success of heart surgeries, thereby improving patient outcomes and providing elegant solutions for healthcare professionals.
Myra Vision
Series A in 2021
Myra Vision is a medical technology company focused on developing innovative treatments for patients with moderate to severe glaucoma. The company aims to enhance intraocular pressure (IOP) reduction through its advanced surgical techniques, which also minimize the risk of hypotony. By addressing the existing gaps in glaucoma therapies, Myra Vision seeks to provide effective solutions that improve patient outcomes and support physicians in managing this challenging condition. Through its novel technology, the company is committed to advancing glaucoma care and improving the quality of life for affected individuals.
Myra Vision
Series A in 2021
Myra Vision is a medical technology company focused on developing innovative treatments for patients with moderate to severe glaucoma. The company aims to enhance intraocular pressure (IOP) reduction through its advanced surgical techniques, which also minimize the risk of hypotony. By addressing the existing gaps in glaucoma therapies, Myra Vision seeks to provide effective solutions that improve patient outcomes and support physicians in managing this challenging condition. Through its novel technology, the company is committed to advancing glaucoma care and improving the quality of life for affected individuals.
Collective Health
Series F in 2021
Collective Health is a health benefits platform that integrates various medical, dental, vision, and pharmacy services into a cohesive solution aimed at simplifying healthcare for employees and their families. The company’s cloud-based platform streamlines the administration of health plans through a single portal, offering clear guidance, live concierge support, and digital tools for managing care. By reducing the administrative burden associated with health benefits, Collective Health enhances the member experience and aids organizations in controlling costs while improving health outcomes. Headquartered in San Francisco, California, the company also has offices in Chicago, Illinois, and Lehi, Utah.
Supira Medical
Series B in 2020
Supira Medical, Inc. is a medical technology company based in Campbell, California, focused on developing a percutaneous ventricular assist device (pVAD) designed for high-risk patients undergoing interventional procedures. This innovative device offers high-flow mechanical support during critical situations such as high-risk percutaneous coronary interventions (PCI) and cardiogenic shock. By assisting the heart's native pumping action, Supira Medical's solution enables patients with severe coronary artery disease or related comorbidities to safely undergo necessary interventions, thereby facilitating quicker recovery from heart-related issues. Founded in 2012 and originally known as Lumenblation Medical, Inc., the company rebranded in March 2016 to reflect its commitment to advancing cardiac care.
CloudCath
Series A in 2020
CloudCath is a company that specializes in developing a sensor-enabled digital platform tailored for patients undergoing peritoneal dialysis. The platform integrates Internet of Things-based sensing hardware with a continuous monitoring system, allowing for the early detection of complications associated with catheter-based treatments. This innovative approach not only enhances patient care by enabling healthcare providers to monitor patients remotely during their home treatments but also aims to reduce the frequency of in-person visits required each month. By focusing on early complication detection, CloudCath seeks to improve patient outcomes in the management of dialysis therapy.
Palantir Technologies
Venture Round in 2019
Palantir Technologies, established in 2003, specializes in developing data integration and analysis platforms. The company offers two primary products: Palantir Gotham, designed for enterprises to manage, secure, and analyze data, and Palantir Metropolis, focused on quantitative data analysis. Palantir serves a wide range of sectors, including government, defense, finance, healthcare, and others, helping them make sense of large, complex data sets. The company is headquartered in Palo Alto, California.
Atia Vision
Series D in 2019
Atia Vision, Inc. is a medical device company based in Campbell, California, specializing in the development of innovative ophthalmic solutions. Founded in 2012, the company focuses on creating modular presbyopia-correcting intraocular lenses, which address the needs of the intraocular lens replacement market. Atia Vision's technology features an accommodating base that responds to the ciliary muscles of the eye, simulating natural accommodation and allowing for subsequent refractive corrections. This approach restores the full range of functional vision for cataract patients, effectively improving patient outcomes by eliminating the need for glasses. The company's commitment to advancing eye care is reflected in its goal to enhance the quality of life for individuals through innovative medical devices that expedite market entry while minimizing risk.
Tioga Cardiovascular
Series A in 2019
Tioga Cardiovascular is a privately held company that specializes in developing valve replacement solutions for mitral and tricuspid applications. The company focuses on creating medical equipment technology that employs a transcatheter approach, which is both procedurally simpler and less invasive than traditional methods. By prioritizing innovation in valve replacement devices, Tioga Cardiovascular aims to enhance the effectiveness and success of heart surgeries, thereby improving patient outcomes and providing elegant solutions for healthcare professionals.
NuVera Medical
Seed Round in 2019
NuVera Medical, Inc. is a privately held company based in Campbell, California, founded in 2016. It specializes in developing an advanced imaging platform that utilizes 4D ultrasound technology for cardiovascular procedures. The platform is designed for real-time intracardiac echocardiography, enabling healthcare specialists to visualize heart chambers during transcatheter cardiac interventions. By simplifying complex cardiovascular procedures, NuVera Medical aims to support cardiologists in making informed decisions throughout their interventions.
Uber
Venture Round in 2019
Uber Technologies, Inc., established in 2009, is a global technology company that connects users with transportation and logistics services through its mobile application. It operates in over 300 cities worldwide, offering a range of services including ridesharing, food delivery, and freight transportation. Uber's core business is facilitating transportation by matching riders with drivers, providing safe, reliable, and convenient options at varying price points. Additionally, Uber Advanced Technologies Group, a subsidiary, focuses on developing self-driving car technology to enhance transportation safety and accessibility.
Atia Vision
Series C in 2018
Atia Vision, Inc. is a medical device company based in Campbell, California, specializing in the development of innovative ophthalmic solutions. Founded in 2012, the company focuses on creating modular presbyopia-correcting intraocular lenses, which address the needs of the intraocular lens replacement market. Atia Vision's technology features an accommodating base that responds to the ciliary muscles of the eye, simulating natural accommodation and allowing for subsequent refractive corrections. This approach restores the full range of functional vision for cataract patients, effectively improving patient outcomes by eliminating the need for glasses. The company's commitment to advancing eye care is reflected in its goal to enhance the quality of life for individuals through innovative medical devices that expedite market entry while minimizing risk.
Supira Medical
Series A in 2018
Supira Medical, Inc. is a medical technology company based in Campbell, California, focused on developing a percutaneous ventricular assist device (pVAD) designed for high-risk patients undergoing interventional procedures. This innovative device offers high-flow mechanical support during critical situations such as high-risk percutaneous coronary interventions (PCI) and cardiogenic shock. By assisting the heart's native pumping action, Supira Medical's solution enables patients with severe coronary artery disease or related comorbidities to safely undergo necessary interventions, thereby facilitating quicker recovery from heart-related issues. Founded in 2012 and originally known as Lumenblation Medical, Inc., the company rebranded in March 2016 to reflect its commitment to advancing cardiac care.
NuVera Medical
Series A in 2017
NuVera Medical, Inc. is a privately held company based in Campbell, California, founded in 2016. It specializes in developing an advanced imaging platform that utilizes 4D ultrasound technology for cardiovascular procedures. The platform is designed for real-time intracardiac echocardiography, enabling healthcare specialists to visualize heart chambers during transcatheter cardiac interventions. By simplifying complex cardiovascular procedures, NuVera Medical aims to support cardiologists in making informed decisions throughout their interventions.
Cerestra
Acquisition in 2016
Cerestra is a private equity firm that specializes in investing in real estate assets that are socially relevant and critical for business. The firm focuses on sectors such as K-12 education infrastructure, student housing, life sciences real estate, and industrial light manufacturing facilities. By providing a platform for innovative and risk-mitigated investment opportunities, Cerestra aims to create a unique investment landscape that fosters strong relationships and proprietary strategies. Through its targeted approach, the firm seeks to address essential needs within these sectors while delivering value to its investors.
Northgate Capital
Acquisition in 2016
Northgate Capital, established in 2000, is a global investment firm with offices in San Francisco, London, and Mexico City. It manages approximately $4.8 billion in assets and employs over 50 investment professionals. The firm specializes in venture capital, offering both fund-of-funds and direct investment strategies, and also operates in private equity, focusing on global small market fund-of-funds, Mexico growth equity, and mezzanine finance.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.